The efficacy and safety of combined pulsed and conventional radiofrequency treatment of refractory cases of idiopathic trigeminal neuralgia: a retrospective study

2015 ◽  
Vol 29 (5) ◽  
pp. 728-733 ◽  
Author(s):  
Ali A. Ali Eissa ◽  
Raafat M. Reyad ◽  
Emad G. Saleh ◽  
Amr El-Saman
Keyword(s):  
Retrospective Study ◽  
Trigeminal Neuralgia ◽  
Efficacy And Safety ◽  
Radiofrequency Treatment ◽  
Idiopathic Trigeminal Neuralgia

scholarly journals Efficacy and Safety of Percutaneous Ozone Injection Around Gasserian Ganglion for the Treatment of Trigeminal Neuralgia: A Multicenter Retrospective Study

2020 ◽  
Vol Volume 13 ◽  
pp. 927-936
Author(s):  
Lei Gao ◽  
Ruo-Wen Chen ◽  
John P. Williams ◽  
Tong Li ◽  
Wei-Jiang Han ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Trigeminal Neuralgia ◽  
Gasserian Ganglion ◽  
Efficacy And Safety ◽  
Ozone Injection

scholarly journals A retrospective study of 72 cases diagnosed with idiopathic trigeminal neuralgia in indian populace

2015 ◽  
pp. e40-e44 ◽  
Author(s):  
S. Yadav ◽  
HC. Mittal ◽  
A. Sachdeva ◽  
A. Verma ◽  
V. Dhupar ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Trigeminal Neuralgia ◽  
Idiopathic Trigeminal Neuralgia

Pulsed radiofrequency treatment of the Gasserian ganglion in patients with idiopathic trigeminal neuralgia

Pain ◽  
2003 ◽  
Vol 104 (3) ◽  
pp. 449-452 ◽  
Author(s):  
Jan Van Zundert ◽  
Steven Brabant ◽  
Erik Van de Kelft ◽  
Alex Vercruyssen ◽  
Jean-Pierre Van Buyten
Keyword(s):  
Trigeminal Neuralgia ◽  
Gasserian Ganglion ◽  
Pulsed Radiofrequency ◽  
Radiofrequency Treatment ◽  
Pulsed Radiofrequency Treatment ◽  
Idiopathic Trigeminal Neuralgia

scholarly journals Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Jing Liu ◽  
Ying-Ying Xu ◽  
Qi-Lin Zhang ◽  
Wei-Feng Luo
Keyword(s):  
Botulinum Toxin ◽  
Trigeminal Neuralgia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Advanced Age ◽  
Efficacy And Safety ◽  
Younger Patients ◽  
Idiopathic Trigeminal Neuralgia ◽  
D Values

Objective. To assess the therapeutic efficacy and safety of botulinum toxin type A (BTX-A) for treating idiopathic trigeminal neuralgia (ITN) in patients ≥80 years old. Methods. Selected patients n=43 with ITN, recruited from the neurology clinic and inpatient department of the Second Affiliated Hospital of Soochow University between August 2008 and February 2014, were grouped by age, one subset n=14 ≥80 years old and another n=29 <60 years old. Each group scored similarly in degrees of pain registered by the visual analogue scale (VAS). Dosing, efficacy, and safety of BTX-A injections were compared by group. Results. Mean dosages of BTX-A were 91.3 ± 25.6 U and 71.8 ± 33.1 U in older and younger patients, respectively t=1.930, p=0.061. The median of the VAS score in older patients at baseline (8.5) declined significantly at 1 month after treatment (4.5) p=0.007, as did that of younger patients (8.0 and 5.0, resp.) p=0.001. The median of the D values of the VAS scores did not differ significantly by group (older, 2.5; younger, 0; Z=−1.073, p=0.283). Two patients in each group developed minor transient side effects p=0.825. Adverse reactions in both groups were mild, resolving spontaneously within 3 weeks. Conclusions. BTX-A is effective and safe in treating patients of advanced age (≥80 years old) with ITN, at dosages comparable to those used in much younger counterparts (<60 years old).

Sign in / Sign up

Export Citation Format

Share Document